Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De‐novo heart transplant recipients: Design of the randomized controlled EVOLVD trial-Reference-Cited by-同舟云学术

Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De‐novo heart transplant recipients: Design of the randomized controlled EVOLVD trial

Published:2020-08-06 Issue:9 Volume:34 Page:
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Broch Kaspar¹,Gude Einar¹,Karason Kristjan²,Dellgren Göran²,Rådegran Göran³⁴,Gjesdal Grunde³,Gustafsson Finn⁵,Eiskjær Hans⁶,Lommi Jyri⁷,Pentikäinen Markku⁷,Lemström Karl B.⁷⁸,Andreassen Arne K.¹,Gullestad Lars¹⁹^ORCID

Affiliation:

1. Department of Cardiology Oslo University Hospital, Rikshospitalet Oslo Norway

2. Transplant Institute Sahlgrenska University Hospital Gothenburg Sweden

3. The Clinic for Heart Failure and Valvular Disease Skåne University Hospital Lund Sweden

4. Lund University Lund Sweden

5. Department of Cardiology Rigshospitalet Copenhagen Denmark

6. Department of Cardiology Aarhus University Hospital Aarhus Denmark

7. Helsinki University Hospital Heart and Lung Center Helsinki Finland

8. University of Helsinki Helsinki Finland

9. KG Jebsen Center for Cardiac Research University of Oslo Norway and Center for Heart Failure Research Oslo University Hospital Norway

Publisher

Wiley